|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2002-6-14
|
|
pubmed:abstractText |
The use of serotonin 5-hydroxytryptamine type 3 receptor antagonists has substantially reduced, but not eliminated, nausea and vomiting in cancer chemotherapy. This study sought to investigate whether efficacy of antiemetic treatment with ondansetron and tropisetron depends on cytochrome P-450 2D6 (CYP2D6) genotype, hypothesizing that the rapid and particularly the ultrarapid metabolizers of these drugs are at risk of being undertreated.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2805-11
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12065557-Adolescent,
pubmed-meshheading:12065557-Adult,
pubmed-meshheading:12065557-Aged,
pubmed-meshheading:12065557-Aged, 80 and over,
pubmed-meshheading:12065557-Antineoplastic Agents,
pubmed-meshheading:12065557-Cytochrome P-450 CYP2D6,
pubmed-meshheading:12065557-Female,
pubmed-meshheading:12065557-Gene Expression Profiling,
pubmed-meshheading:12065557-Genetic Predisposition to Disease,
pubmed-meshheading:12065557-Genotype,
pubmed-meshheading:12065557-Humans,
pubmed-meshheading:12065557-Indoles,
pubmed-meshheading:12065557-Male,
pubmed-meshheading:12065557-Middle Aged,
pubmed-meshheading:12065557-Nausea,
pubmed-meshheading:12065557-Neoplasms,
pubmed-meshheading:12065557-Ondansetron,
pubmed-meshheading:12065557-Polymerase Chain Reaction,
pubmed-meshheading:12065557-Polymorphism, Restriction Fragment Length,
pubmed-meshheading:12065557-Predictive Value of Tests,
pubmed-meshheading:12065557-Prospective Studies,
pubmed-meshheading:12065557-Risk Factors,
pubmed-meshheading:12065557-Serotonin Antagonists,
pubmed-meshheading:12065557-Vomiting
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes.
|
|
pubmed:affiliation |
Institute of Clinical Pharmacology and Department of Hematology and Oncology, University Medical Center Charité, Humboldt University of Berlin, Berlin, Germany. rolf.kaiser@med.uni-goettingen.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
